3,4-Methylenedioxy-N-ethylamphetamine

From WikiMD's WELLNESSPEDIA

(Redirected from Methylenedioxyethylamphetamine)

Chemical structure of 3,4-Methylenedioxy-N-ethylamphetamine

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) is a synthetic entactogen of the amphetamine class. It is chemically related to MDMA and MDA, and is known for its psychoactive effects. MDEA is commonly referred to as "Eve" in the context of recreational use.

Chemical Structure and Properties[edit]

3D model of MDEA

MDEA is a member of the phenethylamine and amphetamine chemical classes. Its chemical structure consists of a methylenedioxy ring attached to the phenyl group, with an ethyl group attached to the nitrogen atom of the ethylamine chain. This structure is similar to that of MDMA, with the primary difference being the ethyl group in place of the methyl group.

Pharmacology[edit]

MDEA acts primarily as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). It increases the levels of these neurotransmitters in the brain, leading to its psychoactive effects. The entactogenic effects of MDEA are attributed to its action on the serotonin system, similar to other drugs in the MDxx family.

Effects[edit]

The effects of MDEA are similar to those of MDMA, though generally considered to be less intense. Users report feelings of euphoria, increased sociability, and enhanced sensory perception. The duration of effects typically lasts 3 to 6 hours, with a peak occurring around 1 to 2 hours after ingestion.

Synthesis[edit]

Synthesis pathway of MDA from safrole

MDEA can be synthesized from safrole, a precursor also used in the synthesis of MDMA and MDA. The synthesis involves several chemical reactions, including the formation of the methylenedioxy ring and the attachment of the ethylamine chain.

Legal Status[edit]

MDEA is classified as a Schedule I controlled substance in many countries, including the United States, under the Controlled Substances Act. This classification indicates that it is considered to have a high potential for abuse and no accepted medical use.

Related Compounds[edit]

  • MDMA (3,4-Methylenedioxy-N-methylamphetamine)
  • MDA (3,4-Methylenedioxyamphetamine)
  • MBDB (3,4-Methylenedioxy-N-methylbutanamine)

Related Pages[edit]

Gallery[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=3,4-Methylenedioxy-N-ethylamphetamine&oldid=6622506"